Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2022-07-28 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2022-07-28 English
FORM 3 SUBMISSION
Director's Dealing
2022-07-28 English
FORM 3 SUBMISSION
Director's Dealing
2022-07-28 English
NYSE AMERICAN CERTIFICATION
Regulatory Filings
2022-07-27 English
8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration, specifically for Maia Biotechnology, Inc. The document length is 3277 characters, which is relatively short and contains no financial statements or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2022-07-27 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1. It requests acceleration of the effective date for the registration statement and discusses compliance with securities regulations. The content is related to the process of securities registration and underwriting, not a financial report or earnings release. The document length is short (1716 characters) and it is a correspondence letter, not a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-07-25 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.